ZIVO Bioscience, Inc. (ZIVO)
USD 16.02
(-15.68%)
USD 16.02
(-15.68%)
| Year | Total Liabilities | Total Liabilities Growth |
|---|---|---|
| 2023 | 2.76 Million USD | 29.43% |
| 2022 | 2.13 Million USD | -27.62% |
| 2021 | 2.94 Million USD | -74.43% |
| 2020 | 11.53 Million USD | 32.42% |
| 2019 | 8.7 Million USD | -61.63% |
| 2018 | 22.69 Million USD | 10.62% |
| 2017 | 20.51 Million USD | 42.87% |
| 2016 | 14.35 Million USD | 50.04% |
| 2015 | 9.56 Million USD | 47.88% |
| 2014 | 6.47 Million USD | -45.01% |
| 2013 | 11.76 Million USD | 180.85% |
| 2012 | 4.19 Million USD | 67.94% |
| 2011 | 2.49 Million USD | 93.17% |
| 2010 | 1.29 Million USD | -69.16% |
| 2009 | 4.18 Million USD | 338.59% |
| 2008 | 954.73 Thousand USD | -7.33% |
| 2007 | 1.03 Million USD | -10.76% |
| 2006 | 1.15 Million USD | -7.65% |
| 2005 | 1.25 Million USD | 8.16% |
| 2004 | 1.15 Million USD | 2424.5% |
| 2003 | 45.78 Thousand USD | 0.0% |
| 2002 | - USD | 0.0% |
| 2001 | - USD | -100.0% |
| 2000 | 1600.00 USD | 0.0% |
| Year | Total Liabilities | Total Liabilities Growth |
|---|---|---|
| 2024 Q1 | 3.08 Million USD | 11.72% |
| 2024 Q2 | 2.87 Million USD | -6.94% |
| 2023 Q2 | 3.85 Million USD | 34.34% |
| 2023 Q1 | 2.86 Million USD | 34.49% |
| 2023 FY | 2.76 Million USD | 29.43% |
| 2023 Q4 | 2.76 Million USD | -13.6% |
| 2023 Q3 | 3.19 Million USD | -17.1% |
| 2022 Q3 | 2.44 Million USD | -14.26% |
| 2022 FY | 2.13 Million USD | -27.62% |
| 2022 Q1 | 3.1 Million USD | 5.28% |
| 2022 Q2 | 2.85 Million USD | -8.04% |
| 2022 Q4 | 2.13 Million USD | -12.81% |
| 2021 Q3 | 3.55 Million USD | -5.82% |
| 2021 Q1 | 12.07 Million USD | 4.7% |
| 2021 Q2 | 3.77 Million USD | -68.77% |
| 2021 FY | 2.94 Million USD | -74.43% |
| 2021 Q4 | 2.94 Million USD | -16.98% |
| 2020 FY | 11.53 Million USD | 32.42% |
| 2020 Q4 | 11.53 Million USD | 2.76% |
| 2020 Q1 | 9.32 Million USD | 7.11% |
| 2020 Q2 | 10.21 Million USD | 9.53% |
| 2020 Q3 | 11.22 Million USD | 9.84% |
| 2019 Q3 | 10.97 Million USD | -2.65% |
| 2019 Q1 | 24.8 Million USD | 9.3% |
| 2019 Q2 | 11.27 Million USD | -54.56% |
| 2019 Q4 | 8.7 Million USD | -20.64% |
| 2019 FY | 8.7 Million USD | -61.63% |
| 2018 Q2 | 19.57 Million USD | -12.39% |
| 2018 FY | 22.69 Million USD | 10.62% |
| 2018 Q4 | 22.69 Million USD | 3.86% |
| 2018 Q1 | 22.34 Million USD | 8.93% |
| 2018 Q3 | 21.85 Million USD | 11.61% |
| 2017 Q4 | 20.51 Million USD | 5.38% |
| 2017 FY | 20.51 Million USD | 42.87% |
| 2017 Q2 | 16.77 Million USD | 1.22% |
| 2017 Q1 | 16.57 Million USD | 15.43% |
| 2017 Q3 | 19.46 Million USD | 16.04% |
| 2016 Q1 | 10.46 Million USD | 9.36% |
| 2016 Q2 | 11.2 Million USD | 7.08% |
| 2016 Q3 | 13.51 Million USD | 20.64% |
| 2016 Q4 | 14.35 Million USD | 6.21% |
| 2016 FY | 14.35 Million USD | 50.04% |
| 2015 Q3 | 8.77 Million USD | 8.68% |
| 2015 Q4 | 9.56 Million USD | 9.06% |
| 2015 Q1 | 7.54 Million USD | 16.52% |
| 2015 FY | 9.56 Million USD | 47.88% |
| 2015 Q2 | 8.07 Million USD | 7.07% |
| 2014 FY | 6.47 Million USD | -45.01% |
| 2014 Q4 | 6.47 Million USD | -32.85% |
| 2014 Q1 | 6.66 Million USD | -43.35% |
| 2014 Q2 | 6.54 Million USD | -1.77% |
| 2014 Q3 | 9.63 Million USD | 47.15% |
| 2013 FY | 11.76 Million USD | 180.85% |
| 2013 Q3 | 12.54 Million USD | 37.79% |
| 2013 Q2 | 9.1 Million USD | 78.62% |
| 2013 Q4 | 11.76 Million USD | -6.22% |
| 2013 Q1 | 5.09 Million USD | 21.68% |
| 2012 FY | 4.19 Million USD | 67.94% |
| 2012 Q4 | 4.19 Million USD | 17.1% |
| 2012 Q3 | 3.57 Million USD | 2.28% |
| 2012 Q2 | 3.49 Million USD | 21.82% |
| 2012 Q1 | 2.87 Million USD | 15.1% |
| 2011 Q3 | 1.66 Million USD | 11.28% |
| 2011 Q4 | 2.49 Million USD | 50.01% |
| 2011 FY | 2.49 Million USD | 93.17% |
| 2011 Q2 | 1.49 Million USD | 5.34% |
| 2011 Q1 | 1.41 Million USD | 9.86% |
| 2010 Q1 | 10.26 Million USD | 145.18% |
| 2010 Q3 | 1.2 Million USD | 13.85% |
| 2010 Q4 | 1.29 Million USD | 7.51% |
| 2010 FY | 1.29 Million USD | -69.16% |
| 2010 Q2 | 1.05 Million USD | -89.72% |
| 2009 Q4 | 4.18 Million USD | 8.52% |
| 2009 Q1 | 1.01 Million USD | 6.48% |
| 2009 FY | 4.18 Million USD | 338.59% |
| 2009 Q2 | 1.02 Million USD | 0.66% |
| 2009 Q3 | 3.85 Million USD | 277.07% |
| 2008 Q1 | 701.69 Thousand USD | -31.89% |
| 2008 FY | 954.73 Thousand USD | -7.33% |
| 2008 Q4 | 954.73 Thousand USD | 8.34% |
| 2008 Q3 | 881.23 Thousand USD | 23.02% |
| 2008 Q2 | 716.34 Thousand USD | 2.09% |
| 2007 Q1 | 1.19 Million USD | 3.62% |
| 2007 FY | 1.03 Million USD | -10.76% |
| 2007 Q4 | 1.03 Million USD | -14.02% |
| 2007 Q3 | 1.19 Million USD | 4.65% |
| 2007 Q2 | 1.14 Million USD | -4.28% |
| 2006 Q2 | 1.2 Million USD | 3.09% |
| 2006 FY | 1.15 Million USD | -7.65% |
| 2006 Q4 | 1.15 Million USD | -3.38% |
| 2006 Q3 | 1.19 Million USD | -1.08% |
| 2006 Q1 | 1.17 Million USD | -6.27% |
| 2005 Q2 | 1.65 Million USD | 13.38% |
| 2005 Q1 | 1.45 Million USD | 26.04% |
| 2005 Q4 | 1.25 Million USD | -15.65% |
| 2005 Q3 | 1.48 Million USD | -10.28% |
| 2005 FY | 1.25 Million USD | 8.16% |
| 2004 FY | 1.15 Million USD | 2424.5% |
| 2004 Q4 | 1.15 Million USD | 90.39% |
| 2004 Q3 | 607.03 Thousand USD | -11.42% |
| 2004 Q2 | 685.29 Thousand USD | 80.16% |
| 2004 Q1 | 380.38 Thousand USD | 730.87% |
| 2003 Q4 | 45.78 Thousand USD | 0.0% |
| 2003 FY | 45.78 Thousand USD | 0.0% |
| 2003 Q2 | - USD | 0.0% |
| 2003 Q1 | - USD | 0.0% |
| 2003 Q3 | - USD | 0.0% |
| 2002 Q2 | - USD | 0.0% |
| 2002 Q1 | - USD | 0.0% |
| 2002 Q3 | - USD | 0.0% |
| 2002 Q4 | - USD | 0.0% |
| 2002 FY | - USD | 0.0% |
| 2001 Q4 | - USD | 0.0% |
| 2001 FY | - USD | -100.0% |
| 2001 Q1 | - USD | -100.0% |
| 2001 Q2 | - USD | 0.0% |
| 2001 Q3 | - USD | 0.0% |
| 2000 Q4 | 1600.00 USD | 0.0% |
| 2000 FY | 1600.00 USD | 0.0% |
| 2000 Q2 | - USD | 0.0% |
| 2000 Q3 | - USD | 0.0% |
| Name | Total Liabilities | Total Liabilities Difference |
|---|---|---|
| America Great Health | 4.82 Million USD | 42.765% |
| Ampio Pharmaceuticals, Inc. | 2.37 Million USD | -16.227% |
| Aridis Pharmaceuticals, Inc. | 38.92 Million USD | 92.906% |
| Biora Therapeutics, Inc. | 132.63 Million USD | 97.918% |
| Bio-Path Holdings, Inc. | 2.77 Million USD | 0.628% |
| Better Therapeutics, Inc. | 23.84 Million USD | 88.417% |
| Calithera Biosciences, Inc. | 8.28 Million USD | 66.664% |
| Comera Life Sciences Holdings, Inc. | 9.97 Million USD | 72.313% |
| Gene Biotherapeutics, Inc. | - USD | -Infinity% |
| eFFECTOR Therapeutics, Inc. | 26.33 Million USD | 89.515% |
| Eloxx Pharmaceuticals, Inc. | 31.78 Million USD | 91.311% |
| Evelo Biosciences, Inc. | 69.43 Million USD | 96.023% |
| Evolutionary Genomics, Inc. | 7.94 Million USD | 65.244% |
| Finch Therapeutics Group, Inc. | 48.11 Million USD | 94.26% |
| Galera Therapeutics, Inc. | 157.32 Million USD | 98.245% |
| Innovation1 Biotech Inc. | 3.5 Million USD | 21.232% |
| Kiromic BioPharma, Inc. | 21.28 Million USD | 87.029% |
| Molecular Templates, Inc. | 31.17 Million USD | 91.141% |
| Navidea Biopharmaceuticals, Inc. | 12.51 Million USD | 77.934% |
| NexImmune, Inc. | 5.08 Million USD | 45.684% |
| Orgenesis Inc. | 35.53 Million USD | 92.229% |
| Panbela Therapeutics, Inc. | 16.51 Million USD | 83.275% |
| Point of Care Nano-Technology, Inc. | 266.41 Thousand USD | -936.566% |
| PaxMedica, Inc. Common Stock | 2.29 Million USD | -20.312% |
| Scopus BioPharma Inc. | 7.45 Million USD | 62.954% |
| Sorrento Therapeutics, Inc. | 494.5 Million USD | 99.442% |
| Statera Biopharma, Inc. | 22.67 Million USD | 87.822% |
| TRACON Pharmaceuticals, Inc. | 10.91 Million USD | 74.697% |
| Trevena, Inc. | 48.26 Million USD | 94.278% |
| Vaxxinity, Inc. | 30.94 Million USD | 91.076% |
| Vaccinex, Inc. | 5.94 Million USD | 53.525% |
| Vicapsys Life Sciences, Inc. | 1.96 Million USD | -40.299% |
| Viracta Therapeutics, Inc. | 38.37 Million USD | 92.803% |